You are in:Home/Publications/RESEARCH ARTICLE CD160 EXPRESSION IN B CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL.)

Dr. Deena A Elshabrawy :: Publications:

Title:
RESEARCH ARTICLE CD160 EXPRESSION IN B CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL.)
Authors: Deena Elshabrawy1, Yasmin Elsakhawy2 and Eman Ibrahim3.
Year: 2017
Keywords: Not Available
Journal: Not Available
Volume: Not Available
Issue: Not Available
Pages: Not Available
Publisher: Not Available
Local/International: International
Paper Link: Not Available
Full paper Deena A Elshabrawy_648_IJAR-18312.pdf
Supplementary materials Not Available
Abstract:

CLL is usually diagnosed through the charachteristic morphology/immunophenotype of the lymphocytes, but some CLL cases remain atypical resulting in uncertain diagnosis. CD160 is a glycosylphosphatidylinositol-Linked receptor found on normal natural killer (NK) and T cells, but not B cells. Its activation protects against apoptosis and increase mean cell viability. The aim of the study is to analyze expression of CD160 in B-CLL and if there is relation with clinical and laboratory parameters. CD 160 expression was assessed using Flow Cytometry, in 60 newly diagnosed CLL patients in addition to 30, matched age and sex, normal subjects who served as a control group. We found that, CD160 was expressed on a greater percentage of B-CLL cells in patients than in control group (p< 0.01) with very high sensitivity (96.7%) and specificity (100%) , so it can represent a useful diagnostic tool in B-CLL cases. There was no significant difference of CD160 expression in various stages in Binet and Rai staging. We demonstrated a significant statistical positive correlation between CD160 and CD20 (p< 0.05) and a highly significant statistical positive correlation between CD160 and CD19 and CD38 (p< 0.01). No significant correlation was found between CD160 and CD23, CD79b, SIgM, FMC7, CD5 and CD10.There was no significant statistical correlation between CD160 and Hemoglobin level(Hb), platelet count(PLT), total leukocytic count(TLC), Absolute and relative lymphocytic count, bone marrow lymphocytes (BML) and Lactate dehydrogenase(LDH). We concluded that; CD160 was expressed on a greater percentage of B-CLL cells in patients than in control group with very high sensitivity and specificity, so it can represent a useful diagnostic tool in B-CLL cases. CD160 expression may be useful prognostic marker in patients with B- CLL.

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus